Form D · Biotechnology
BeneVir Biopharm, Inc.
Gaithersburg, MD · CIK 0001626108
Offering snapshot reported Nov 16, 2017 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $2M Reported outside-investor minimum
- First sale
- Oct 17, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 16, 2017 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
| Aug 31, 2016 | Amendment | $6,000,000 | $4,000,000vs Nov 24, 2014 | 1 | SEC filing |
| Feb 16, 2016 | Initial | $3,000,000 | No comparison | 1 | SEC filing |
| Nov 24, 2014 | Initial | $2,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Debt, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-298906
Convertible Promissory Note and the shares of common stock or preferred stock issuable upon conversion.
Source: Form D, filed Nov 16, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David Kirn | Director |
| Matthew Charles Mulvey | Director, Executive |
| Cherine Plumaker | Director |
| David Present | Director |
| Katherine Ann Sacksteder | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
708 Quince Orchard Road Suite 150
Gaithersburg, MD, 20878
Gaithersburg, MD, 20878